PRF Technologies Ltd. PRFX PHARMA
Company Overview
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company was formerly known as PainReform Ltd. and changed its name to PRF Technologies Ltd. in January 2026. PRF Technologies Ltd. was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.30.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -86.97% |
| 6 Months: | -63.93% |
| 3 Months: | -35.27% |
| 1 Month: | -9.13% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.53 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 92.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRFX PRF Technologies Ltd. PHARMA | 0.94 | -0.23 | $3.29M | 0.00% | -53.59% | -45.33% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 17.00K |
| Cost of Revenue | - | - | 0 | 0 | 70.00K |
| Gross Profit | - | - | 0 | 0 | -53.00K |
| Operating Expenses | - | 8.87M | 9.58M | 14.67M | 5.07M |
| Operating Income | - | -8.87M | -9.58M | -14.67M | -5.12M |
| EBITDA | - | -8.85M | -9.57M | -14.66M | -4.35M |
| Interest Expense | 0 | 0 | - | - | - |
| Pretax Income | - | -8.78M | -9.34M | -14.58M | -5.01M |
| Tax Provision | - | 9.00K | 8.00K | 8.00K | 8.00K |
| Net Income | - | -8.79M | -9.34M | -14.59M | -5.02M |
| Diluted EPS | -870.00 | -317.30 | -122.94 | -105.52 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 12.33M | 9.93M | 4.53M | 12.00M |
| Current Assets | - | 12.28M | 9.80M | 4.43M | 4.35M |
| Cash & Equivalents | - | 4.10M | 8.03M | 4.26M | 3.12M |
| Inventory | - | - | - | - | - |
| Receivables | - | 55.00K | 45.00K | 119.00K | 142.00K |
| Total Liabilities | - | 1.31M | 2.69M | 2.70M | 2.71M |
| Current Liabilities | - | 1.06M | 2.41M | 2.44M | 2.44M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | 86.00K | 45.00K | 21.00K |
| Total Equity | - | 11.02M | 7.24M | 1.82M | 8.54M |
| Shares Outstanding | - | 8.86K | 14.40K | 294.28K | 402.63K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -6.46M | -6.68M | -12.62M | -3.96M |
| Investing Cash Flow | - | -6.01M | 5.99M | -13.00K | -982.00K |
| Financing Cash Flow | - | 0 | 4.62M | 8.86M | 3.82M |
| Capital Expenditure | - | -6.00K | -9.00K | -13.00K | -2.00K |
| Free Cash Flow | - | -6.46M | -6.69M | -12.63M | -3.96M |
| Net Change in Cash | - | -12.46M | 3.93M | -3.77M | -1.12M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | -311.8% |
| Operating Margin % | - | - | - | - | -30,129.4% |
| Net Margin % | - | - | - | - | -29,541.2% |
| ROE % | - | -79.8% | -129.1% | -799.8% | -58.8% |
| ROCE % | - | -78.7% | -127.4% | -704.4% | -53.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Yorkville Advisors Global, LP | 2.67% | 81.10K | $82.72K |
| 2 | Jane Street Group, LLC | 2.64% | 80.39K | $81.99K |
| 3 | Citadel Advisors Llc | 0.94% | 28.57K | $29.15K |
| 4 | UBS Group AG | 0.34% | 10.41K | $10.62K |
| 5 | Morgan Stanley | 0.09% | 2.78K | $2.84K |
| 6 | Royal Bank of Canada | 0.01% | 233 | $237 |
| 7 | Rockefeller Capital Management L.P. | - | 1 | $1 |
| 8 | Osaic Holdings Inc. | - | 40 | $40 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRFX
Painreform Stock Price Forecast. Should You Buy PRFX? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1EYnFZeGw4M2NmV0JXb3EwVnpfc0tmTUhPcEx0OTJzOExhenBqNXZEVUtwNExFQ2dHQzRuRUdrandNaG1SUXg0OQ?oc=5" target="_blank">Painreform Stock Price Forecast. Should You Buy PRFX?</a> …
PRF Technologies Ltd. SEC Filing (Sep 4, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQdHZla2pLUzRrdndYVk1HUmYtaF9QQjNUckxCdHdncDZmTHhBY19QUVp4b180UGNZTUhJYllRUjVkRlUwbDljeURad0pYbl9FdmpRTGxYOE9jM25RNFAxUWZjQXRwaFl0RzRtV0dhV1pKNl9aUWhIX0tzaWlfcXFuTDR2a0ZMOWh0R2o5NE…
Why Is PRF Tech Stock Falling On Monday? - PRF Technologies (NASDAQ:PRFX) - Benzinga
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOTVFRaXN3SHhVbmZvMmZEandFd2N3S29HdzBBSElrR3JTWEpidWc4SHAxS2NqVDhCY2plQWVZYVhSMkRmTWt3bmNDb09tSUQ2eGRmOXNmOFF3dzl0c1V0NlZFb3dsdm5Cc210NmRiS1RuYmRoS0dudTFZYXI4M2FzZnBBU3U2N2R3UFpJeT…
PRFX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE53U21jUXZ0OXQ4ZGFKbjkyeDJLUGpFQWdzLWpBYzk3QzRFQmtpVVV4bXp4b0lTdW52bWxjMFQ3clBacWtMNVE?oc=5" target="_blank">PRFX</a> <font color="#6f6f6f">Finviz</font>…
PRF Technologies Ltd. (PRFX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMiTEFVX3lxTFBQbDR4QU5VTHFabjN2Z3h3ZFEzY2JRR2poblE4X29UaEMzY3NFQ1JwRXUtd1NTeEJzTTk5MkVyUWVCMDdBaHBLRHJQbHc?oc=5" target="_blank">PRF Technologies Ltd. (PRFX) Stock Price | Live Quotes & Charts …
FDA clears a trial to test a drug ring for cataract surgery. It could eliminate eye drops. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQQ3dqZkFkd2NiX2IxWkc5UlJpc2l6VzMyUkVzdGR4MlF3ZktDdlNSNmZlY1pZZy1oV2Y4V00waUR0ZXdVRURCTFdkRFoxQmJOQS1DVnVKakc4RllKWkR5cUtpV1czNlJ6RWRXNVRKbjdaT24zelBTcno3b3JHSGxSQVpOUjhzUGswU3dGMG…
PRFX — Frequently Asked Questions
What is the current share price of PRF Technologies Ltd. (PRFX)?
As of 2026-09-19 21:16 PDT, PRF Technologies Ltd. (PRFX) trades at $0.94 on NasdaqCM. Its 52-week range is $0.94 to $11.85.
What is the market capitalisation of PRFX?
PRF Technologies Ltd. (PRFX) has a market capitalisation of $3.29M on NasdaqCM.
What is the P/E ratio of PRFX?
PRFX trades at a trailing price-to-earnings (P/E) ratio of -0.23. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.10.
What is the return on equity (ROE) of PRFX?
PRFX has a return on equity (ROE) of -45.33%. Its return on capital employed (ROCE) is -53.59%.
Is PRFX a good stock to buy?
This page provides a data-driven analysis of PRF Technologies Ltd. (PRFX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.